SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Pentixapharm Advances Preparations for Phase 3 PANDA Study

Pentixapharm Holding AG reported progress in preparations for its Phase 3 PANDA study.

Related stories